# NCT02872025 (NCT02872025)

> Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02872025
- Phase: EARLY_PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Laura Esserman
- Conditions: Carcinoma, Intraductal, Noninfiltrating
- Interventions: Pembrolizumab; Intralesional mRNA 2752
- Enrollment: 42
- Primary outcome: Maximum tolerated dose (MTD)
- Primary outcome: Number of participants with Dose-limiting toxicities (DLTs)
- Primary outcome: Percentage of patients who demonstrate an increase (baseline vs. post intralesional injection) in intralesional CD8+ T cells

## Indexed commentary on NCT02872025 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- Podcasts: 1
- X threads: 1
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct02872025